NewAmsterdam Pharma

$NewAmsterdam Pharma(NAMS)$
NewAmsterdam Pharma (NAMS) 是一家处于商业前期的临床阶段生物制药公司，专注于开发治疗心血管疾病及相关代谢性疾病的口服疗法。其核心战略是围绕其主打产品 obicetrapib——一种强效、选择性胆固醇酯转移蛋白（CETP）抑制剂，重新定义降脂治疗格局。
公司...

$NewAmsterdam Pharma(NAMS)$ III 期 PREVAIL 2024年末例入完，超9500例患者，随访2-4年。 近期股价一直心电图走势，公司现金流约还8亿。 先不论成功与否，花费如此大时间，金钱，人力，如果不成功，这还能看得下去$美国生科ETF-SPDR(XBI)$

1、全球范围内血脂仍未达标的极高危/高危患者人数约5000万～1.6亿；
2、目前数据比较突出的$默沙东(MRK)$ PCSK9抑制剂近三年销售额平均每年约30亿；
3、$NewAmsterdam Pharma(NAMS)$ 的Obicetrapib明年若心血管结局试验全部达标，峰值有得想象？
话说如果顺利推进，后续再冲击他汀类一...

$NewAmsterdam Pharma(NAMS)$ SCHEDULE 13D/A [Amend] General Statement of Acquisition of Beneficial Ownership Accession Number: 0001193125-25-308141  Act: 34  Size: 15 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-335513  Size: 22 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001193125-26-008300  Act: 34  Size: 269 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-029526  Size: 13 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ FMR LLC已提交13G表格，报告持有NEWAMSTERDAM PHARMA COMPANY NV的6,412,984股普通股，占该类别股份的5.7%。该文件表明，FMR LLC是在正常业务过程中获得这些股份，并非为了改变发行人的控制权。文件还指出，虽然FMR LLC拥有处置这些股份的唯一权力，但一个或多个其他...

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001968582-25-001282  Act: 33  Size: 4 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-006662  Size: 9 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001974494-26-000013  Act: 33  Size: 4 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001974494-26-000017  Act: 33  Size: 5 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-009271  Size: 7 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-009274  Size: 7 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0000315066-26-000486  Act: 34  Size: 11 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0000950130-25-000295  Act: 33  Size: 4 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-025012  Size: 17 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001974494-26-000015  Act: 33  Size: 4 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-009269  Size: 7 KB 网页链接

$NewAmsterdam Pharma(NAMS)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001422849-25-000077  Act: 34  Size: 7 KB 网页链接